Total Payments
$1.1M
2024 Payments
$109,612
Companies
58
Transactions
2,688
Medicare Patients
1,655
Medicare Billing
$134,148
Payment Breakdown by Category
Other$992,499 (89.1%)
Travel$71,424 (6.4%)
Food & Beverage$40,277 (3.6%)
Consulting$9,036 (0.8%)
Education$316.46 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $981,175 | 711 | 88.1% |
| Travel and Lodging | $71,424 | 403 | 6.4% |
| Food and Beverage | $40,277 | 1,543 | 3.6% |
| Compensation for serving as faculty or as a speaker for a medical education program | $10,724 | 4 | 1.0% |
| Consulting Fee | $9,036 | 8 | 0.8% |
| Honoraria | $600.00 | 1 | 0.1% |
| Education | $316.46 | 18 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $421,275 | 610 | $0 (2024) |
| Lilly USA, LLC | $276,091 | 721 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $181,498 | 254 | $0 (2020) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $159,578 | 304 | $0 (2024) |
| Amgen Inc. | $24,599 | 78 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $20,807 | 35 | $0 (2024) |
| Dexcom, Inc. | $16,623 | 77 | $0 (2024) |
| Corcept Therapeutics | $2,961 | 36 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,743 | 107 | $0 (2023) |
| SANOFI-AVENTIS U.S. LLC | $1,073 | 63 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $109,612 | 376 | Lilly USA, LLC ($51,563) |
| 2023 | $152,404 | 412 | Lilly USA, LLC ($77,716) |
| 2022 | $171,651 | 352 | Lilly USA, LLC ($70,068) |
| 2021 | $96,159 | 185 | Novo Nordisk Inc ($64,088) |
| 2020 | $75,280 | 169 | Lilly USA, LLC ($30,625) |
| 2019 | $131,476 | 369 | Novo Nordisk Inc ($54,707) |
| 2018 | $155,686 | 371 | Novo Nordisk Inc ($63,529) |
| 2017 | $221,283 | 454 | Janssen Pharmaceuticals, Inc ($105,833) |
All Payment Transactions
2,688 individual payment records from CMS Open Payments — Page 1 of 108
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Travel and Lodging | Cash or cash equivalent | $98.60 | General |
| Category: Diabetes | ||||||
| 12/19/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Travel and Lodging | Cash or cash equivalent | $33.50 | General |
| Category: Diabetes | ||||||
| 12/19/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Travel and Lodging | Cash or cash equivalent | $32.00 | General |
| Category: Diabetes | ||||||
| 12/19/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | Cash or cash equivalent | $16.79 | General |
| Category: Diabetes | ||||||
| 12/18/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $650.00 | General |
| Category: Diabetes | ||||||
| 12/17/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,400.00 | General |
| Category: Diabetes | ||||||
| 12/17/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,225.00 | General |
| Category: Diabetes | ||||||
| 12/17/2024 | Acella Pharmaceuticals, LLC | NP Thyroid 60 (Drug) | Food and Beverage | In-kind items and services | $27.82 | General |
| Category: Hyperthyroidism | ||||||
| 12/16/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,275.00 | General |
| Category: DIABETES | ||||||
| 12/16/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $650.00 | General |
| Category: DIABETES | ||||||
| 12/16/2024 | Xeris Pharmaceuticals, Inc. | RECORLEV (Drug) | Food and Beverage | In-kind items and services | $22.94 | General |
| Category: Adrenal steroidogenesis inhibitor | ||||||
| 12/16/2024 | Xeris Pharmaceuticals, Inc. | RECORLEV (Drug) | Education | In-kind items and services | $12.25 | General |
| Category: Adrenal steroidogenesis inhibitor | ||||||
| 12/13/2024 | SANOFI-AVENTIS U.S. LLC | TZIELD (Biological) | Food and Beverage | In-kind items and services | $28.01 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 12/13/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $10.77 | General |
| Category: DIABETES | ||||||
| 12/11/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,300.00 | General |
| Category: DIABETES | ||||||
| 12/11/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $232.84 | General |
| 12/11/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | Cash or cash equivalent | $125.25 | General |
| Category: Diabetes | ||||||
| 12/09/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $650.00 | General |
| Category: DIABETES | ||||||
| 12/09/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Travel and Lodging | Cash or cash equivalent | $75.04 | General |
| Category: Diabetes | ||||||
| 12/09/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Travel and Lodging | Cash or cash equivalent | $5.90 | General |
| Category: Diabetes | ||||||
| 12/07/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $17.37 | General |
| Category: Diabetes | ||||||
| 12/06/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,300.00 | General |
| Category: Diabetes | ||||||
| 12/06/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $650.00 | General |
| Category: Diabetes | ||||||
| 12/05/2024 | Novo Nordisk Inc | Rybelsus (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $750.00 | General |
| Category: Diabetes | ||||||
| 12/05/2024 | Antares Pharma, Inc. | XYOSTED (Drug) | Food and Beverage | In-kind items and services | $17.26 | General |
| Category: TESTOSTERONE REPLACEMENT THERAPY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 554 | 873 | $146,361 | $49,319 |
| 2022 | 6 | 445 | 607 | $103,747 | $36,207 |
| 2021 | 6 | 306 | 396 | $78,543 | $28,143 |
| 2020 | 5 | 350 | 456 | $76,632 | $20,480 |
Total Patients
1,655
Total Services
2,332
Medicare Billing
$134,148
Procedure Codes
33
All Medicare Procedures & Services
33 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 161 | 312 | $73,320 | $28,197 | 38.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 93 | 93 | $33,294 | $10,696 | 32.1% |
| 76536 | Ultrasound scan of head and neck soft tissue | Office | 2023 | 41 | 44 | $11,880 | $3,487 | 29.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 26 | 29 | $4,582 | $1,864 | 40.7% |
| 10005 | Fine needle aspiration biopsy using ultrasound guidance, first growth | Office | 2023 | 13 | 13 | $5,525 | $1,392 | 25.2% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 31 | 51 | $5,100 | $1,243 | 24.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 11 | 11 | $2,585 | $875.90 | 33.9% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 68 | 85 | $5,610 | $809.20 | 14.4% |
| 82962 | Blood glucose (sugar) test performed by hand-held instrument | Office | 2023 | 110 | 235 | $4,465 | $754.35 | 16.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 143 | 249 | $43,575 | $15,203 | 34.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 83 | 107 | $23,585 | $9,095 | 38.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 61 | 61 | $21,660 | $7,776 | 35.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 16 | 16 | $4,304 | $1,432 | 33.3% |
| 76536 | Ultrasound scan of head and neck soft tissue | Office | 2022 | 13 | 13 | $3,510 | $1,179 | 33.6% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Facility | 2022 | 19 | 21 | $1,533 | $492.03 | 32.1% |
| 83036 | Hemoglobin a1c level | Office | 2022 | 38 | 42 | $2,730 | $399.93 | 14.6% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2022 | 12 | 13 | $1,300 | $356.72 | 27.4% |
| 82962 | Blood glucose (sugar) test performed by hand-held instrument | Office | 2022 | 60 | 85 | $1,550 | $273.04 | 17.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 111 | 157 | $27,475 | $12,023 | 43.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 52 | 84 | $17,012 | $5,657 | 33.3% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 35 | 35 | $9,415 | $3,581 | 38.0% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 46 | 46 | $14,547 | $3,064 | 21.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 11 | 12 | $2,820 | $1,369 | 48.5% |
| 95251 | Ambulatory continuous glucose (sugar) including interpretation and report for a minimum of 72 hours | Facility | 2021 | 26 | 34 | $2,482 | $935.34 | 37.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 13 | 16 | $2,272 | $824.87 | 36.3% |
About Dr. Basil Burney, M.D
Dr. Basil Burney, M.D is a Endocrinology, Diabetes & Metabolism healthcare provider based in Colleyville, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/11/2007. The National Provider Identifier (NPI) number assigned to this provider is 1043414485.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Basil Burney, M.D has received a total of $1.1M in payments from pharmaceutical and medical device companies, with $109,612 received in 2024. These payments were reported across 2,688 transactions from 58 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($981,175).
As a Medicare-enrolled provider, Burney has provided services to 1,655 Medicare beneficiaries, totaling 2,332 services with total Medicare billing of $134,148. Data is available for 4 years (2020–2023), covering 33 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location Colleyville, TX
- Active Since 06/11/2007
- Last Updated 03/01/2023
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1043414485
Products in Payments
- JARDIANCE (Drug) $290,536
- INVOKANA (Drug) $181,433
- MOUNJARO (Drug) $134,475
- Ozempic (Drug) $133,201
- Tresiba (Drug) $85,262
- Rybelsus (Drug) $67,604
- RYBELSUS (Drug) $57,923
- Victoza (Drug) $35,093
- Repatha (Biological) $24,005
- Kerendia (Drug) $18,395
- Xultophy 100/3.6 (Drug) $12,830
- Dexcom G6 Transmitter (Medical Supply) $12,744
- Korlym (Drug) $2,961
- DEXCOM G6 TRANSMITTER (Device) $2,040
- FARXIGA (Drug) $1,737
- Dexcom CGM (Device) $1,440
- Vascepa (Drug) $695.04
- Minimed 670G System (Device) $528.16
- Saxenda (Drug) $484.25
- TOUJEO (Drug) $478.23
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.